| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00954512 2009-011101-16 Details | 2018-08-24 Interventional | 1/2 | 15 | Carboplatin Cetuximab Epirubicin Everolimus Folic Acid Gemcitabine Irinotecan Leucovorin Levoleucovorin Trastuzumab Neoplasms | This study was terminated for business reasons. - | |||
| NCT02663752 Details | 2018-08-23 Interventional | 2 | 1 | Deferasirox Myelodysplastic… Preleukemia Syndrome Myelodysplastic… | - The trial was terminated due to low enrollment. | |||
| NCT02329756 Details | 2018-08-23 Interventional | 3 | 0 | Tranexamic Acid Placenta Accret… | More preparation needed prior to collecting data. - | |||
| NCT00847223 Details | 2018-08-23 Interventional | 2 | 11 | Tipifarnib Lymphoma Lymphoma, Mantl… Mantle Cell Lym… | Inefficiency of treatment - | |||
| NCT00617890 Details | 2018-08-23 Interventional | 2 | [1 Refs] | 219 | Antibodies, Mon… Neuroectodermal… Neuroectodermal… Neuroectodermal… Osteosarcoma Sarcoma Sarcoma, Ewing Peripheral Neur… Sarcoma, Ewing'… | The study was prematurely terminated for strategic reasons, not for a safety concern. The study was stopped prematurely for administrative reasons; not all planned endpoints were analyzed. | ||
| NCT00300573 2006-000096-16 Details | 2018-08-23 Interventional | 2 | 250 | Dexelvucitabine Acquired Immuno… HIV Infections Human Immunodef… | Development program ended due to inability to pair with other cytidine analogs and higher risk
of hyperlipasemia when not used with 3TC/FTC. - | |||
| NCT02632903 Details | 2018-08-22 Interventional | 2 | 0 | Zoledronic Acid Leukemia Osteonecrosis Osteoporosis Precursor Cell … Acute Lymphobla… | While the clinical need for and the scientific merit remain valid, this regulated drug trial
was not feasible logistically due to limited funds. - | |||
| NCT01847014 Details | 2018-08-22 Interventional | 3 | 4 | Macitentan Familial Primar… Hypertension Pulmonary Arter… | Protocol-defined criterion of macitentan availability achieved. - | |||
| NCT00930241 Details | 2018-08-22 Interventional | 3 | 25 | Tacrolimus Lung Transplant… | logistic reasons (insufficient funding, technical problems with MEMS) - | |||
| NCT02770729 Details | 2018-08-21 Interventional | 3 | 3640 | Moxifloxacin Norgestimate, e… Endophthalmitis | - - | |||
| NCT02762617 Details | 2018-08-21 Interventional | 1 | [1 Refs] | 17 | Tenofovir HIV Healthy | Safety-related - | ||
| NCT01425996 Details | 2018-08-21 Interventional | 1/2 | 3 | Camptothecin Carcinoma Carcinoma, Hepa… | - - | |||
| NCT00415857 Details | 2018-08-21 Interventional | 2 | 5 | Imatinib Mesyla… Peginterferon a… Sargramostim Vaccines Leukemia | Vaccine sponsor ceased operations. - | |||
| NCT02684084 Details | 2018-08-20 Interventional | 4 | 5 | Dexamethasone Ranibizumab Edema Macular Edema Diabetic Macula… | Study revised significantly. New trial to be launched. - | |||
| NCT02386098 Details | 2018-08-20 Interventional | 2 | 86 | Atazanavir Sulf… BMS-955176 Dolutegravir Ritonavir Tenofovir HIV Infections | GI Intolerability - | |||
| NCT01695759 Details | 2018-08-20 Interventional | 3 | 92 | Epoetin Alfa Anemia Kidney Diseases Renal Insuffici… Chronic Kidney … | - - | |||
| NCT01673490 Details | 2018-08-20 Interventional | 4 | 59 | Dutasteride Tamsulosin Hyperplasia Prostatic Hyper… | The sole investigative site refused to accept the amended protocol and declined to continue the
study. There was no safety signal nor any other reason. - | |||
| NCT00688597 Details | 2018-08-17 Interventional | 2 | 3 | 1-Deoxynojirimy… Glycogen Storag… Pompe Disease | Per protocol, 3 sequential dose cohorts were planned. Study discontinued by Sponsor based upon
serious adverse events in first 2 of 3 participants in Cohort 1. The serious adverse event of muscle weakness was the main contributor to the study not reaching the target number of participants needed to achieve target power and statistically reliable results. | |||
| NCT03285607 Details | 2018-08-16 Interventional | 1 | 0 | Cyclophosphamid… Doxorubicin Paclitaxel Breast Neoplasm… Breast Cancer Cancer of Breas… | Drug provider decided not to move forward with the study. - | |||
| NCT01943019 Details | 2018-08-16 Interventional | 1 | 1 | Linagliptin Schizophrenia | Inability to obtain patients - |